Age-related macular degeneration (ARMD) is the commonest cause of visual impairment leading to blind registration among older adults in the western world. Following recently published trials, ophthalmologists around the world now have the knowledge and the drugs to improve visual outcomes and to provide much-needed hope to patients with wet macular degeneration. Further, many research trials are currently under way with more funding to find an even more suitable and effective treatment modality for macular degeneration.